Development of PowerMag System II for Isolation of Circulating Tumor Cells with Improved Purity

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2025 Feb 26

PMID 40002844

Authors

Cheng-Rou Ho

Hui-Ju Tsai

Jin-Ru Wang

Chia-Te Wang

Chiuan-Chian Chiou

Ju-Chien Cheng

Sum-Fu Chiang

Ching-Ping Tseng

Affiliations

Soon will be listed here.

Abstract

: The PowerMag system (PM) is a platform for the isolation of circulating tumor cells (CTCs) by the depletion of CD45-leukocytes. However, an EpCAMCD45 cell population is present in large numbers in the cell filtrates collected by PM. This lowers the purity of the CTCs and negatively impacts their molecular characterization. The aims of this study are to characterize the cellular properties of the EpCAMCD45 cells and to upgrade the system to improve CTC purity. : A real-time RT-PCR assay, Liu's stain analysis, and Annexin V (AnxV) binding assay were used to define the cellular properties of the EpCAMCD45 cells. An upgraded system was developed to remove the EpCAMCD45 cells and improve the CTC purity. Clinical blood samples were used to evaluate the performance of the system. : The EpCAMCD45 cells were defined as apoptotic cells, which displayed apoptotic body-like morphology and elicited AnxV binding activity. AnxV beads developed in-house can effectively bind and remove EpCAMCD45 cells from the cell filtrates. An improved generation of a CTCs isolation platform, designated as PM II, was developed by integration of AnxV beads into the workflow to remove the apoptotic cells. PM II recovered CTCs with improved CTC purity by effective removal of the background apoptotic cells. The improved performance of PM II allowed for direct profiling of cancer-related gene mutations by next-generation sequencing without cell picking and further purification. : PM II holds great promise as a platform for isolating CTCs with improved purity and for exploring its application in cancer diagnosis and monitoring in a clinical setting.

References

Xie W, Suryaprakash S, Wu C, Rodriguez A, Fraterman S . Trends in the use of liquid biopsy in oncology. Nat Rev Drug Discov. 2023; 22(8):612-613. DOI: 10.1038/d41573-023-00111-y. View

Danecek P, Bonfield J, Liddle J, Marshall J, Ohan V, Pollard M . Twelve years of SAMtools and BCFtools. Gigascience. 2021; 10(2). PMC: 7931819. DOI: 10.1093/gigascience/giab008. View

Deng G, Herrler M, Burgess D, Manna E, Krag D, Burke J . Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res. 2008; 10(4):R69. PMC: 2575542. DOI: 10.1186/bcr2131. View

Forbes S, Bhamra G, Bamford S, Dawson E, Kok C, Clements J . The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet. 2008; Chapter 10:Unit 10.11. PMC: 2705836. DOI: 10.1002/0471142905.hg1011s57. View

Campton D, Ramirez A, Nordberg J, Drovetto N, Clein A, Varshavskaya P . High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining. BMC Cancer. 2015; 15:360. PMC: 4430903. DOI: 10.1186/s12885-015-1383-x. View

Millner L, Linder M, Valdes Jr R . Circulating tumor cells: a review of present methods and the need to identify heterogeneous phenotypes. Ann Clin Lab Sci. 2013; 43(3):295-304. PMC: 5060940. View

Cristofanilli M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Semin Oncol. 2006; 33(3 Suppl 9):S9-14. DOI: 10.1053/j.seminoncol.2006.03.016. View

Li P, Mao Z, Peng Z, Zhou L, Chen Y, Huang P . Acoustic separation of circulating tumor cells. Proc Natl Acad Sci U S A. 2015; 112(16):4970-5. PMC: 4413297. DOI: 10.1073/pnas.1504484112. View

Desitter I, Guerrouahen B, Benali-Furet N, Wechsler J, Janne P, Kuang Y . A new device for rapid isolation by size and characterization of rare circulating tumor cells. Anticancer Res. 2011; 31(2):427-41. View

10.

Xu C, Gu X, Padmanabhan R, Wu Z, Peng Q, Dicarlo J . smCounter2: an accurate low-frequency variant caller for targeted sequencing data with unique molecular identifiers. Bioinformatics. 2018; 35(8):1299-1309. PMC: 6477992. DOI: 10.1093/bioinformatics/bty790. View

11.

Dransfield I, Buckle A, Savill J, McDOWALL A, Haslett C, Hogg N . Neutrophil apoptosis is associated with a reduction in CD16 (Fc gamma RIII) expression. J Immunol. 1994; 153(3):1254-63. View

12.

Griwatz C, Brandt B, Assmann G, Zanker K . An immunological enrichment method for epithelial cells from peripheral blood. J Immunol Methods. 1995; 183(2):251-65. DOI: 10.1016/0022-1759(95)00063-g. View

13.

Sherry S, Ward M, Kholodov M, Baker J, Phan L, Smigielski E . dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2000; 29(1):308-11. PMC: 29783. DOI: 10.1093/nar/29.1.308. View

14.

Nagrath S, Sequist L, Maheswaran S, Bell D, Irimia D, Ulkus L . Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007; 450(7173):1235-9. PMC: 3090667. DOI: 10.1038/nature06385. View

15.

Grigoryeva E, Tashireva L, Alifanov V, Savelieva O, Vtorushin S, Zavyalova M . The Novel Association of Early Apoptotic Circulating Tumor Cells with Treatment Outcomes in Breast Cancer Patients. Int J Mol Sci. 2022; 23(16). PMC: 9408919. DOI: 10.3390/ijms23169475. View

16.

Rau K, Liu C, Hsiao Y, Hsiao K, Wang T, Hung W . Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response. J Clin Med. 2020; 9(1). PMC: 7019972. DOI: 10.3390/jcm9010188. View

17.

Shegekar T, Vodithala S, Juganavar A . The Emerging Role of Liquid Biopsies in Revolutionising Cancer Diagnosis and Therapy. Cureus. 2023; 15(8):e43650. PMC: 10505053. DOI: 10.7759/cureus.43650. View

18.

Tseng C, Leong K, Liou M, Hsu H, Lin H, Chen Y . Circulating epithelial cell counts for monitoring the therapeutic outcome of patients with papillary thyroid carcinoma. Oncotarget. 2017; 8(44):77453-77464. PMC: 5652792. DOI: 10.18632/oncotarget.20512. View

19.

Nanduri L, Hissa B, Weitz J, Scholch S, Bork U . The prognostic role of circulating tumor cells in colorectal cancer. Expert Rev Anticancer Ther. 2019; 19(12):1077-1088. DOI: 10.1080/14737140.2019.1699065. View

20.

Sequist L, Nagrath S, Toner M, Haber D, Lynch T . The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. J Thorac Oncol. 2009; 4(3):281-3. PMC: 4486079. DOI: 10.1097/JTO.0b013e3181989565. View